Have you been hearing a lot about acetaminophen lately?

July 7th, 2009

Don’t panic– chances are, you can keep taking the painkiller without any worry.

FDA proposing new rules to reduce painkiller overdoses

June 30th, 2009

Their actions are prompted by studies showing that 56,000 people visit the ER annually due to liver failure from acetaminophen overdose.

PhRMA: Medicaid carve-out would hurt patients & taxpayers

June 24th, 2009

The Pharmaceutical Research and Manufacturers of America say that carving drug coverage out of the Medicaid program would disrupt treatment for patients, among other consequences.

How much will the federal government save with new prescription drug plan of action?

June 23rd, 2009

President Obama and other groups are praising pharmaceutical companies’ promise to lower drug prices for Medicare patients who fall into the coverage gap, but some Senates say that the government won’t benefit from the deal.

Rendell proposes expanding PACENET

June 3rd, 2009

His proposal would raise the income limit for PACENET, the state program that gives prescription drug benefits to older Pennsylvanians.

Rendell trying again to get support for pharmacy plan

June 1st, 2009

Medicaid “carve-out” would have patients receive medications through the Dept. of Public Welfare.

York Co. program gets prescription discounts for residents AND their pets

May 28th, 2009

The York Dispatch calls it a “win-win situation.”

Prices for brand-name prescriptions drugs rising; generic drugs falling

April 17th, 2009

Meanwhile, drug companies are spending less to advertise their medications.

John Baer of the Philadelphia Daily News: Pols get another chance to do right

April 8th, 2009

Baer urges Pennsylvanians to urge the legislature approve a bill that would authorize the Dept. of Public Welfare to purchase prescription drugs for those who receive medical assistance.

Obama admin wants to change the rules for generics

March 31st, 2009

As part of its drive to cut health-care costs, the Obama administration wants to stop the payments pharmaceutical companies make to generic-drug makers to delay the launch of cheap copies, reports the Wall Street Journal.